Solifenacin

PBAC's latest decision on Solifenacin: Recommended with restriction (2010). Considered for detrusor overactivity in a patient who cannot tolerate oral oxybutynin.

Eligible population

patients who cannot tolerate oral oxybutynin

Therapy area

Urology

Line of therapy

Later-line

Evidence base

RCT, Single-arm

Primary endpoint

QoL, INCONTINENCE EPISODES, MICTURITIONS

Key trials

VENUS, VIBRANT, SUNRISE, CL-013, CL-014, CL-015, CL-018, CL-037

Comparator

transdermal oxybutynin

Economic model

Cost-minimisation

ICER note

Cost minimisation analysis — no ICER calculated by design

ICER (historical)

$45k/QALY–$105k/QALY in an earlier submission (2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

Submission history

• Jul 2007: Not recommended — ICER $105k/QALY
• Jul 2010: Recommended with restriction · Restricted Benefit